CAR T start-up Link Cell appointed a new leadership team as it builds out its allogeneic approach to autoimmune therapeutics. The company named Jie D’Elia as CEO, with Friedrich Graf Finckenstein joining as CMO and Brian Slingerland taking an Executive Chair role. The management move signals a push to operationalize a cell-therapy platform positioned for broader access than personalized cancer CAR T models. Leadership additions are often timed ahead of key translational milestones, manufacturing strategy decisions, and early clinical expansions. For the field, Link Cell’s structure mirrors growing interest in off-the-shelf immune reset strategies that could mitigate manufacturing and scalability constraints.